Oncolytics Biotech (ONCY) Announces Publication of Preclinical Data Demonstrating Synergistic Anticancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors


News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) today announced the publication of preclinical data demonstrating the synergistic anticancer activity of pelareorep combined with chimeric antigen receptor (CAR) T-cell therapy in solid tumors. The article, titled “Oncolytic virus-mediated expansion of dual-specificity CAR T cells enhances efficacy against solid tumors in mice,” was published in Science Translational Medicine in collaboration with researchers from several prestigious institutions, including the Mayo Clinic and Duke University. A link to the document can be found by click here.

“The publication of these results in such a high-impact journal provides important external validation of their significance,” said Thomas Heineman, MD, Ph.D., Medical Director of Oncolytics Biotech Inc. “While CAR T cells have generated long term heals in haematological malignancies1, immunosuppressive tumor microenvironments (TME) solid organ cancers have so far limited their efficacy in these indications. Pelareorep has been repeatedly shown to reverse immunosuppressive TMEs, and in the present publication Pelareorep has been shown to enable CAR T cell efficacy in several murine solid tumor models. This is a powerful discovery that, if applied in the clinic, could significantly improve the prognosis of patients with a variety of highly prevalent cancers by providing a novel and potentially lasting treatment option. By demonstrating the ability to improve T cell perseverance, reduce antigen leakage, and overcome difficult TMEs of solid tumors, the inclusion of pelareorep solves the three most challenging barriers to effective CAR T therapy. »

Andrew de Guttadauro, President of Oncolytics Biotech US and Global Head of Business Development, added: “Despite revolutionizing the treatment of certain cancers and exceeding $1 billion in sales last year, CAR T therapies are not currently serve only a small subset of patients with hematological diseases. With these latest results, we now have strong preclinical evidence that pelareorep can fully unlock the value of CAR T therapies by expanding their commercial potential to the much larger market of battling cancer patients. solid tumors.”

Preclinical studies published in the article evaluated the persistence and efficacy of pelareorep-loaded CAR T cells (“CAR/Pela therapy”) in several murine solid tumor models. The effects of combining CAR/Pela therapy with a subsequent intravenous dose of pelareorep (“pelareorep boost”) were also studied. Key data and findings from the article include:

  • The persistence and anticancer activity of CAR T cells was significantly enhanced when loaded with pelareorep. Compared to either treatment alone, treatment with CAR/Pela therapy resulted in statistically significant survival benefits in mouse models of skin and brain cancer.
  • CAR/Pela therapy followed by a pelareorep booster led to increased efficacy in mouse models of skin and brain cancer and tumor cure in >80% of treated mice in each model.
  • Loading CAR T cells with pelareoep improved cancer cell targeting and prevented antigen leak live by generating dual-specificity CAR T cells that target their engineered antigen and the native antigen of the T cell receptor. These results indicate that CAR/Pela therapy may provide longer lasting therapeutic benefits compared to treatment with CAR T cells alone.

Dr. Matt Coffey, President and CEO of Oncolytics Biotech Inc. and co-author of the article, commented, “These exciting results are a great example of how we are leveraging collaborations with industry leaders. opinion and leading research institutes to expand the potential of pelareorep therapeutic impact. This keeps us primarily focused on our core breast cancer program, which has shown how pelareorep’s ability to promote tumor T-cell infiltration leads to synergy with checkpoint inhibitors in the clinic. These recently published preclinical results show that the synergistic benefits of pelareorep extend even beyond checkpoint inhibitors and highlight an opportunity to increase our addressable patient population. As we pursue this opportunity in the future, we intend to utilize relationships with academic or industry partners so that we can continue to execute our clinical and corporate objectives effectively.


Comments are closed.